Precisely! Your experience in ATX paying off here with common sense.
A phase 2 in cholangiocarcinoma is not commercially viable. Patent cliff for CF33 is 2037. Cholangiocarcinoma is a very rare cancer type, which means recruitment is slow. If you assume a minimum of 6 years more clinical work for phase 1/2 and 3, you have a market patent life of 7 years for a slice of 8,000 patients in a contested market. This is before you take into consideration there are no established synergies that have proven efficacy in humans. This means more time required for clinical development, and more uncertainty around market capture. For example, is CF33 given with Keytruda+Chemo as an add on to harmonize with established market, or do you go CF33+Chemo against Keytruda+Chemo. In any case, there is substantial clinical and commercial risk factors.
IMU Price at posting:
3.8¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)